Market Research Logo

Checkpoint Inhibitors for Anti-Cancer Treatment Market 2019-2029

Checkpoint Inhibitors for Anti-Cancer Treatment Market 2019-2029

The 152-page report provides clear detailed insight into the global checkpoint inhibitors for anti-cancer treatment market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

  • Global Checkpoint Inhibitors Anti-Cancer Treatment Market forecasts from 2018-2029
  • Global Checkpoint Inhibitors Anti-Cancer Treatment Market forecasts from 2018-2029 by Leading Drugs:
  • Yervoy (ipilimumab)
  • Opdivo (nivolumab)
  • Keytruda (pembrolizumab)
  • Global Checkpoint Inhibitors Anti-Cancer Treatment Market forecasts from 2018-2029 by Class:
  • CTLA-4 Inhibitors
  • PD-1 Inhibitors
  • Pipeline Drugs
  • Checkpoint Inhibitors Anti-Cancer Treatment Market forecasts from 2018-2029 by regional and national market:
  • U.S.
  • EU: Germany, France, Italy, U.K., Spain
  • Japan
  • APAC
  • Profiles of the selected leading companies:
  • AstraZeneca, Plc
  • Bristol-Myers Squibb Co.
  • Celldex Therapeutics, Inc.
  • Incyte Corporation
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Roche Holding AG
  • The Checkpoint Inhibitors Anti-Cancer Treatment Market Pipeline Analysis
  • A SWOT analysis of the global checkpoint inhibitors anti-cancer treatment market
  • Key Questions Answered by this Report:
  • What are the global revenue prospects for the period 2018 to 2029?
  • What are the leading national market potentials from 2018 to 2029?
  • How is the checkpoint inhibitor anti-cancer treatment drugs market evolving?
  • What is driving and restraining the checkpoint inhibitor anti-cancer treatment drugs market?
  • What are the market shares of each segment of the overall checkpoint inhibitor anti-cancer treatment drugs market?
  • How will main checkpoint inhibitor anti-cancer treatment submarket segments develop over the forecast period and how much revenue will these submarkets account for in 2029?
  • How will the market shares for each checkpoint inhibitor anti-cancer treatment submarket develop from 2018 to 2029?
  • Which therapies can succeed and what revenues could they generate to 2029?
  • What will be the main commercial drivers for the market from 2018 to 2029?
  • How will market shares of prominent national markets change from 2018, and which countries will lead the market in 2029, achieving highest revenues and fastest growth?
  • How will that industry evolve between 2018 and 2029, especially in R&D?
Visiongain’s study is intended for anyone requiring commercial analyses for the Global Checkpoint Inhibitors Anti-Cancer Treatment Drugs Market. You find data, trends and predictions.

Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

The publisher is using a password system to access all reports. Single user (non-printable) and departmental licenses expires after 12 month period. In the case of departmental site license purchases, the publisher requires all email addresses for the licensed users prior to fulfillment.


1. Report Overview
1.1 Global Overview of the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market 2018
1.2 Benefits of This Report
1.3 How This Report Delivers
1.4 Key Questions Answered by This Analytical Report
1.5 Who is This Report For?
1.6 Methods of the Study
1.7 Frequently Asked Questions (FAQ)
1.8 Associated Visiongain Reports
1.9 About Visiongain
2. Introduction to the Checkpoint Inhibitor Anti-Cancer Treatment Drugs World Market 2018
2.1 Checkpoint Inhibitors: A New Era in Immunotherapy
2.2 Checkpoint Inhibitor Treatment Drugs in Oncology
2.3 Application Segment
2.3.1 Lung Cancer
2.3.2 Bladder Cancer
2.3.3 Melanoma
2.3.4 Hodgkin Lymphoma
3. Leading Checkpoint Inhibitors Anti-Cancer Treatment Drugs Market Forecasts 2019-2029 and Leading Companies in the World Market
3.1 Leading Checkpoint Inhibitor Anti-Cancer Treatment Drugs in the Market 2019
3.1.1 Yervoy (ipilimumab) – Bristol-Myers Squibb
3.1.1.1 Yervoy: Sales Analysis
3.1.2 Opdivo (nivolumab) – Bristol-Myers Squibb/Ono Pharmaceutical
3.1.2.1 Opdivo: Sales Analysis
3.1.3 Keytruda (pembrolizumab) – Merck & Co.
3.1.3.1 Keytruda: Sales Analysis
3.2 Leading Companies in the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market in 2018
3.2.1 Bristol-Myers Squibb Leads the Market
4. Checkpoint Inhibitor Anti-Cancer Treatment Drugs: World Market 2019-2029
4.1 The Global Market for Checkpoint Inhibitor Anti-Cancer Treatments in 2018
4.2 The World Checkpoint Inhibitors Anti-Cancer Treatment Drugs Market: Revenue Forecasts 2019-20
4.3 Leading Checkpoint Inhibitor Anti-Cancer Treatment Drugs Submarkets Forecast 2019-2029
4.3.1 The CTLA-4 Inhibitors Submarket Forecast 2019-2029
4.3.2 The PD-1 Inhibitors Submarket Forecast 2019-2029
4.3.3 Changing Market Shares: PD-1 Inhibitors Will Lead the Market
4.3.4 Market Dynamics of the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market 2019-2029
4.3.4.1 Drivers of the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market
4.3.4.2 Restraints of the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market
4.3.4.3 Opportunity of the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market
4.3.4.4 Trends of the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market
5. Leading National Markets for the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market 2019-2029
5.1 Epidemiology of Major Cancer types
5.1.1 Lung Cancer
5.1.2 Bladder Cancer
5.1.3 Melanoma
5.1.4 Hodgkin Lymphoma
5.1.5 Pancreatic Cancer
5.2 Regional Breakdown of the World Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market 2019-2029
5.3 World Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Regional Forecast, 2019-2029
5.3.1 How Will Regional Market Shares Change by 2029?
5.4 The US Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Forecast 2019-2029
5.5 The EU Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Forecast 2019-2029
5.5.1 Germany: The Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Forecast 2019-2029
5.5.2 France: The Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Forecast 2019-2029
5.5.3 Italy: The Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Forecast 2019-2029
5.5.4 The UK: The Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Forecast 2019-2029
5.5.5 Spain: The Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Forecast 2019-2029
5.6 Japan: The Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Forecast 2019-2029
5.7 The APAC Market: Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Forecast 2019-2029
6. The Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Pipeline Analysis 2019-2029
6.1 Anti-PD-1 Inhibitors and Anti-PD-L1 Inhibitors
6.1.1 Tecentriq (Atezolizumab)
6.1.2 Pidilizumab (CT-011) – CureTech, Ltd.
6.1.3 AMP-224 – GSK/Amplimmune
6.1.4 REGN2810 – Regeneron/Sanofi
6.1.5 Libtayo
6.2 CTLA-4 Inhibitors
6.2.1 Tremelimumab (CP-675,206) - AstraZeneca
6.3 LAG-3 (lymphocyte activation gene-3) Inhibitors
6.3.1 IMP321- Prima Biomed
6.3.2 BMS-986016 - Bristol-Myers Squibb
6.3.3 IMP701 – Prima BioMed/Novartis
6.4 KIR Inhibitors
6.4.1 Lirilumab (IPH2102/BMS-986015) – Innate Pharma/Bristol-Myers Squibb
6.5 Anti-NKG2A Inhibitors
6.5.1 IPH2201 – Innate Pharma/AstraZeneca/MedImmune
6.6 Other Checkpoint Inhibitors
6.6.1 VISTA Inhibitors
6.6.1.1 CA-170 – Curis Inc/Aurigene Discovery Technologies
6.6.1.2 NLG919 – NewLink Genetics
6.6.1.3 INCB024360 – Incyte/Roche
6.6.2 A2aR Inhibitors
6.6.2.1 HTL-1071 – AstraZeneca/Heptares
6.7 Clinical trial landscape for Immune checkpoint inhibitors
6.8 Clinical trial landscape for pd1/L1 Immune checkpoint inhibitors
7. Qualitative Analysis of the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market 2019-2029
7.1 SWOT Analysis of the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market 2019-2029
7.1.1 Strengths and Weaknesses of the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market
7.1.1.1 A Novel Treatment Method that Harnesses the Immune System’s Vast Potential
7.1.1.2 Pricing of the Treatments Will Attract Companies
7.1.1.3 Cost of Treatment Will Restrain Market Access
7.1.1.4 Side Effects May Prohibit Growth
7.1.2 Opportunities and Threats for the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market
7.1.2.1 Biomarkers Pave the Way for Optimum Utility
7.1.2.2 Combination Therapies are Achieving Superior Results
7.1.2.3 The Cost Burden of Expensive Drug Treatments on Healthcare Systems
7.1.2.4 Crowding of the Market with Similar Products
8. Company Profiles
8.1 AstraZeneca Plc.
8.1.1 Company Overview
8.1.2 Key Developments
8.2 Bristol-Myers Squibb Co.
8.2.1 Company Overview
8.2.2 Key Developments
8.3 Celldex Therapeutics Inc.
8.3.1 Company Overview
8.3.2 Key Developments
8.4 Incyte Corporation
8.4.1 Company Overview
8.4.2 Key Developments
8.5 Merck & Co., Inc.
8.5.1 Company Overview
8.5.2 Key Developments
8.6 Novartis Ag
8.6.1 Company Overview
8.6.2 Key Developments
8.7 Pfizer Inc.
8.7.1 Company Overview
8.7.2 Key Developments
8.8 Roche Holding Ag
8.8.1 Company Overview
8.8.2 Key Developments
9. Conclusions
9.1 The Global Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Current World Outlook
9.1.1 Driver for Growth: A Robust and Innovative Pipeline for the Checkpoint Inhibitors Anti-Cancer Treatment Drugs Market to 2029
9.2 Leading National Markets for the Checkpoint Inhibitor Anti-Cancer Treatment Market 2019-2029: The US and EU Will Retain Their Lead
9.3 The Future of the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market
Appendices
Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain report evaluation form
List of Tables
Table 2.1 Main Types of Checkpoint Inhibitors in Development, 2018
Table 3.1 Yervoy (Ipilimumab): Historical Sales ($bn, AGR%), 2015-2018
Table 3.2 Yervoy Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2018-2024
Table 3.3 Yervoy Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2024-2029
Table 3.4 Opdivo Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2024
Table 3.5 Opdivo Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2025-2029
Table 3.6 Keytruda Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2018-2024
Table 3.7 Keytruda Forecast, Revenue ($bn), Annual Growth (%), CAGR (%),2024-2029
Table 3.8 Leading Companies in the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Revenue ($bn), Market Share (%), 2018
Table 4.1 Global Market for Checkpoint Inhibitor Anti-Cancer Treatment Drugs: Revenues ($bn) and Market Shares (%) by Class, 2018
Table 4.2 Checkpoint Inhibitors by Revenue ($bn), 2018
Table 4.3 Checkpoint Inhibitors by Revenue ($bn), 2018
Table 4.4 Global Market Forecast for Checkpoint Inhibitors Anti-Cancer Treatment Drugs by Class: Market Sizes ($bn), Annual Growth Rates (%), CAGR (%), 2018-2024
Table 4.5 Global Market Forecast for Checkpoint Inhibitors Anti-Cancer Treatment Drugs by Class: Market Sizes ($bn), Annual Growth Rates (%), CAGR (%), 2024-2029
Table 4.6 Global Market for Checkpoint Inhibitors Anti-Cancer Treatment Drugs: Revenues ($bn) and Market Shares (%) by Class, 2018
Table 4.7 Global Market Forecast for CTLA-4 Inhibitors: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2018-2024
Table 4.8 Global Market Forecast for CTLA-4 Inhibitors: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2024-2029
Table 4.9 Global Market Forecast for PD-1 Inhibitors: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2018-2024
Table 4.10 Global Market Forecast for PD-1 Inhibitors: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2024-2029
Table 4.11 Global Market Forecast for Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market by Class: Market Shares (%), 2018-2024
Table 4.12 Global Market Forecast for Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market by Class: Market Shares (%), 2024-2029
Table 5.1 Regional and National Breakdown of the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Sizes ($bn), Market Shares (%), 2018
Table 5.2 Forecast of Regional and National Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Sizes ($bn), Annual Growth (%), CAGRs (%), 2018-2024
Table 5.3 Forecast of Regional and National Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Sizes ($bn), Annual Growth (%), CAGRs (%), 2024-2029
Table 5.4 Forecast of Regional and National Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Shares (%), 2018-2024
Table 5.5 Forecast of Regional and National Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Shares (%), 2024-2029
Table 5.6 Forecast of the US Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2018-2024
Table 5.7 Forecast of the US Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2024-2029
Table 5.8 EU Market Shares (%), 2018-2024
Table 5.9 EU Market Shares (%), 2024-2029
Table 5.10 Forecast of the EU Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2018-2024
Table 5.11 Forecast of the EU Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2024-2029
Table 5.12 Forecast of the German Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2018-2024
Table 5.13 Forecast of the German Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2024-2029
Table 5.14 Forecast of the French Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2018-2024
Table 5.15 Forecast of the French Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2024-2029
Table 5.16 Forecast of the Italian Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2018-2024
Table 5.17 Forecast of the Italian Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2024-2029
Table 5.18 Forecast of the UK Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2018-2024
Table 5.19 Forecast of the UK Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2024-2029
Table 5.20 Forecast of the Spanish Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2018-2024
Table 5.21 Forecast of the Spanish Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2024-2029
Table 5.22 Forecast of the Japanese Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2018-2024
Table 5.23 Forecast of the Japanese Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2024-2029
Table 5.24 Forecast of the APAC Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2018-2024
Table 5.25 Forecast of the APAC Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2024-2029
Table 6.1 Selected Combination Therapies for Atezolizumab, 2018
Table 6.2 Tecentriq Forecast: Revenue ($bn), 2018-2024
Table 6.3 Tecentriq Forecast: Revenue ($bn), 2024-2029
Table 6.4 Libtayo Forecast: Revenue ($bn), 2018-2024
Table 6.5 Tremelimumab Forecast: Revenue ($bn), 2018-2024
Table 6.6 Tremelimumab Forecast: Revenue ($bn), 2024-2029
Table 7.1 Strengths and Weaknesses of the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market, 2018
Table 7.2 Opportunities and Threats of the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market, 2018
Table 8.1 AstraZeneca PLC. Profile 2018
Table 8.2: AstraZeneca: Key Developments
Table 8.3 Bristol-Myers Squibb Co. Profile 2018
Table 8.4: Bristol-Myers Squibb: Key Developments
Table 8.5 Celldex Therapeutics Inc. Profile 2018
Table 8.6: Celldex Therapeutics: Key Developments
Table 8.7 Incyte Corporation Profile 2018 (
Table 8.8: Incyte: Key Developments
Table 8.9 Merck & Co., Inc. Profile 2018
Table 8.10: Merck & Co.: Key Developments
Table 8.11 Novartis AG Profile 2018
Table 8.12: Novartis: Key Developments
Table 8.13 Pfizer Inc. Profile 2018 (
Table 8.14: Pfizer: Key Developments
Table 8.15: Roche Holding AG Profile 2018 (
Table 8.16: Roche: Key Developments
Table 9.1 Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Forecast by Region: Market Size ($bn), Market Share (%), CAGR (%), 2018, 2020, 2024, and 2029
Table 9.2 Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Forecasts by Class: Market Size ($bn) Market Share (%), CAGR (%), 2018, 2020, 2024, and 2029
List of Figures
Figure 1.1 Global Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Segmentation Overview, 2019
Figure 3.1 Yervoy (ipilimumab): Historical Sales ($bn), 2015-2018
Figure 3.2 Yervoy Forecast, Revenue ($bn), 2018-2029
Figure 3.3 Opdivo Forecast, Revenue ($bn), 2018-2029
Figure 3.4 Keytruda Forecast, Revenue ($bn), 2018-2029
Figure 3.5 Leading Companies in the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market by Revenue: Market Shares, 2018 (%)
Figure 4.1 Global Market for Checkpoint Inhibitor Anti-Cancer Treatment Drugs: Market Shares by Class (%), 2018
Figure 4.2 Global Market Forecast for Checkpoint Inhibitors Anti-Cancer Treatment Drugs by Class: Market Sizes ($bn), 2018-2029
Figure 4.3 Global Market for Checkpoint Inhibitors Anti-Cancer Treatment Drugs: Market Shares by Class (%), 2018
Figure 4.4 Global Market Forecast for CTLA-4 Inhibitors: Revenue ($bn), 2018-2029
Figure 4.5 Global Market Forecast for PD-1 Inhibitors: Revenue ($bn), 2018-2029
Figure 4.6 Global Market for Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Shares by Class (%), 2024

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report